In December 2024, RMMS secured a favorable appeal outcome on behalf of its client, MSN Pharmaceuticals, Inc. (et al.), in connection with litigation involving Novartis Pharmaceuticals Corp.’s drug for the treatment of heart failure, Entresto® (sacubitril/valsartan).
More specifically, on December 4, 2024, the Federal Circuit affirmed the district court’s denial of Novartis’s motion for preliminary injunction in connection with U.S. Patent No. 11,096,918. In particular, the Federal Circuit affirmed the district court finding that Novartis was not likely to succeed on the issue of infringement.
This victory solidifies RMMS’ reputation as a leading appellate option in connection with litigation regarding pharmaceutical patents.
Members of the RMMS team representing MSN included William A. Rakoczy, Kevin E. Warner, and Ty W. Callahan.
The opinion can be read here.